title: Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
authors.forename: C
authors.initials: C
authors.lastname: Schoch
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: W
authors.initials: W
authors.lastname: Kern
authors.forename: S
authors.initials: S
authors.lastname: Schnittger
authors.forename: U
authors.initials: U
authors.lastname: Berger
authors.forename: R
authors.initials: R
authors.lastname: Hehlmann
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002869:Chromosome Aberrations; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate